# Clinical and Metabolic Predictors of Response to Focused Extracorporeal Shockwave Therapy in Rotator Cuff Tendinopathy: A Retrospective Cohort Study

**Authors:** Sveva Maria Nusca, Eleonora Latini, Gabriele Santilli, Gioia Beccarini, Valerio Bova, Flavia Santoboni, Valter Santilli, Giorgio Felzani, Fabrizio Perroni, Mariachiara Vulpiani, Davide Sisti, Mario Vetrano

PMC · DOI: 10.3390/medsci14010114 · Medical Sciences · 2026-02-27

## TL;DR

This study finds that baseline severity and BMI predict how well patients respond to shockwave therapy for shoulder tendon issues.

## Contribution

The study identifies baseline severity and BMI as key predictors of ESWT effectiveness in rotator cuff tendinopathy.

## Key findings

- Baseline clinical severity was the strongest predictor of improvement in all models.
- Higher BMI was associated with less functional improvement after ESWT.
- 91.2% of patients reported excellent or good outcomes based on the Roles and Maudsley score.

## Abstract

Background: Rotator cuff tendinopathy is a major cause of shoulder pain and disability. Focused extracorporeal shockwave therapy (ESWT) is an established conservative treatment option; however, the predictive factors influencing the treatment response remain poorly characterized. Objectives: To identify clinical, demographic, and metabolic predictors of pain reduction and functional improvement at four months following focused ESWT in patients with supraspinatus tendinopathy, with the goal of informing individualized treatment planning and early prognostic counseling. Methods: This retrospective cohort study analyzed patients with supraspinatus tendinopathy (calcific and non-calcific) treated with focused ESWT at a university rehabilitation center between June 2020 and December 2025. Outcomes were assessed at baseline and 4-month follow-up using the Visual Analog Scale (VAS), Roles and Maudsley, and Constant–Murley scores. Change score analysis with covariate adjustment and backward stepwise selection were performed to identify predictors of clinical improvement. Results: A total of 239 patients (97 males [40.6%], 142 females [59.4%]; mean age 60.2 ± 11.5 years; mean BMI 25.5 ± 4.0 kg/m2) were included, of whom 101 (42.3%) had calcific tendinopathy. Significant improvements were observed in all outcomes: VAS decreased from 6.50 ± 1.35 to 3.96 ± 2.09 (p < 0.001; Cohen’s d = 1.24), and Constant–Murley score increased from 60.38 ± 14.53 to 75.88 ± 15.52 (p < 0.001; Cohen’s d = 1.07). Patient-reported satisfaction (Roles and Maudsley score) showed a 91.2% success rate (excellent or good outcomes). Regression analysis identified baseline severity as the strongest predictor of improvement in all models. BMI emerged as a significant predictor of functional recovery (β = −0.95, p < 0.001 for Constant–Murley change), with each 1 kg/m2 increase associated with approximately 1-point less improvement. Conclusions: Baseline clinical severity and body mass index were consistent predictors of ESWT effectiveness in rotator cuff tendinopathy. A lower BMI was associated with greater functional improvement, highlighting a potentially modifiable factor for treatment optimization. These findings support personalized treatment planning and early prognostic counseling in clinical practices.

## Full-text entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, BMP2 (bone morphogenetic protein 2) [NCBI Gene 650] {aka BDA2, BMP2A, SSFSC, SSFSC1}
- **Diseases:** overweight (MESH:D050177), rheumatic disease (MESH:D012216), calcific tendinopathy (MESH:D052256), malignancy (MESH:D009369), impingement syndrome (MESH:D019534), shoulder pain (MESH:D020069), nerve block (MESH:D006327), hyperlipidemia (MESH:D006949), musculoskeletal problems (MESH:D009140), coagulopathy (MESH:D001778), thyroid disease (MESH:D013959), musculoskeletal pain (MESH:D059352), inflammation (MESH:D007249), limitation (MESH:D045745), adiposity (MESH:D018205), hypertension (MESH:D006973), calcification (MESH:D002114), adhesive capsulitis (MESH:D002062), Rotator Cuff Tendinopathy (MESH:D000070636), Shoulder disorders (MESH:D000070599), obese (MESH:D009765), kinesiophobia (MESH:D000092442), infection (MESH:D007239), injury to (MESH:D014947), diabetes mellitus (MESH:D003920), Pain (MESH:D010146), fatty degeneration (MESH:D008067), hypercholesterolemia (MESH:D006937)
- **Chemicals:** glycosaminoglycan (MESH:D006025)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13027989/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13027989/full.md

## References

68 references — full list in the complete paper: https://tomesphere.com/paper/PMC13027989/full.md

---
Source: https://tomesphere.com/paper/PMC13027989